Albert Bourla
Bourla receives acclaim for operational skill and leadership, yet his acquisition decisions and R&D oversight have drawn criticism, affecting Pfizer’s expansion.
Although successful with Pfizer’s Covid vaccine, Bourla’s emphasis on reputation and delayed response to downturns have limited his capacity to boost growth.
Sources note Bourla’s forceful goal-setting as a double-edged sword, while Pfizer’s preference for homegrown leaders raises concerns about succession.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.